Triple-negative
breast cancer (TNBC) is an aggressive type of breast
cancer for which effective therapies are lacking. Targeted remodeling
of the immunosuppressive tumor microenvironment (TME) and activation
of the body’s immune system to fight tumors with well-designed
nanoparticles have emerged as pivotal breakthroughs in tumor treatment.
To simultaneously remodel the immunosuppressive TME and trigger immune
responses, we designed two potential therapeutic nanodelivery systems
to inhibit TNBC. First, the bromodomain-containing protein 4 (BRD4)
inhibitor JQ1 and the cyclooxygenase-2 (COX-2) inhibitor celecoxib
(CXB) were coloaded into chondroitin sulfate (CS) to obtain CS@JQ1/CXB
nanoparticles (NPs). Then, the biomimetic nanosystem MM@P3 was prepared
by coating branched polymer poly(β-amino ester) self-assembled
NPs with melittin embedded macrophage membranes (MM). Both in vitro and in vivo, the CS@JQ1/CXB and
MM@P3 NPs showed excellent immune activation efficiencies. Combination
treatment exhibited synergistic cytotoxicity, antimigration ability,
and apoptosis-inducing and immune activation effects on TNBC cells
and effectively suppressed tumor growth and metastasis in TNBC tumor-bearing
mice by activating the tumor immune response and inhibiting angiogenesis.
In summary, this study offers a novel combinatorial immunotherapeutic
strategy for the clinical TNBC treatment.